AltruBio

| name = AltruBio, Inc. | logo = | type = Private | foundation = Taipei City, Taiwan (2000 (2000)) | location_city = San Francisco, CA | location_country = United States

| key_people =

• Judy Chou (President and CEO)

| industry = pharmaceutical industry | products = ALTB-268 therapy for autoimmune disorders | homepage = www.altrubio.com/altrubio/en | footnotes = }}AltruBio is an American biopharmaceutical company based in San Francisco, CA and incorporated under the laws of Delaware. It was founded in 2000 under the name "AbGenomics" and changed to its present name in 2020 . Its research labs are located in Taipei, Taiwan.

Since 2021, the executive leadership of AltruBio is comprised of Judy Chou, President and CEO, Jeroen Grasman, CFO, Jesse Hall, CMO, and Gene Lee, CTO.

Investors

In April 2021, AltruBio received $63M in preferred stock financing from aMoon Fund, Caxton Alternative Management/CAM Capital and Biotechnology Value Fund/BVF Partners L.P. with additional participation from Taiwan based investors.

Technology

The lead program, ALTB-268, is a first-in-class tetravalent [1] antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases. ALTB-268 is a more potent version of the first generation molecule, ALTB-168. ALTB-168 is a bivalent antibody, which has been tested in over 200 patients in four different indications, including Psoriasis , Psoriatic Arthritis, Ulcerative Colitis and acute Graft-versus-Host disease. ALTB-268 is currently being tested in an open label clinical study for Ulcerative Colitis.

References

This article "AltruBio" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:AltruBio. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• Jim Power
• Rob Gasson
• Lee Felix
• Witekio Holding
• Kamaran Ihsan Salih
• Beatriz Vasquez
• Andrews and Partners

---